Keeping HER2 therapy when your heart function is weaker
Treatments studied
Part of Cancer, Heart & circulation, Skin clinical trials.
This trial studies whether it’s safe to continue HER2-targeted breast cancer treatment (like trastuzumab, pertuzumab, or T-DM1) even when heart function (left ventricle) is reduced. It may help people avoid stopping a helpful cancer medicine because of heart concerns.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage I to III HER2-positive breast cancer
- You are currently receiving adjuvant or neoadjuvant HER2 therapy (trastuzumab, pertuzumab, or T-DM1)
- Recent heart testing shows left ventricle dysfunction (lower pumping strength) or symptoms of mild heart failure
- You must NOT be taking both an ACE inhibitor/ARB and a beta-blocker at the same time
- You can’t have severe heart failure symptoms (NYHA class III or IV), very low LVEF (<40%), or low blood pressure (systolic <100)
- You must not be pregnant or breastfeeding (and must not plan to be)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks how well the heart handles HER2-targeted therapy (like Herceptin) during the first year of treatment for early-stage breast cancer. It helps keep you safe by checking heart function closely.
This study looks at different types of HER2-positive breast cancer to learn more about the disease. It is for people with early-stage or locally advanced breast cancer who have not yet received treatment, and aims to help doctors find better ways to personalize care.
This trial tests whether switching between two targeted therapy combinations can help women with HER2-positive advanced breast cancer that has progressed after previous treatments. It aims to find a new effective option for people who have already tried one or two lines of therapy.
This Phase 2 study tests a shorter schedule of trastuzumab and pertuzumab combined with chemotherapy (taxanes) to reduce breast cancer coming back after surgery. It mainly helps people with early-stage, HER2-positive breast cancer that has not spread, by testing whether a shorter plan still works well and is tolerable.
This trial tests if a newer drug, Trastuzumab Rezetecan, works as well as an approved drug, Trastuzumab Deruxtecan, when given before surgery for HER2-positive breast cancer. It aims to see which one helps shrink tumors more effectively.
This trial tests a combination of two drugs—trastuzumab deruxtecan (a targeted therapy) and lovastatin (a statin)—to treat advanced or metastatic breast cancer that has low levels of a protein called HER2. The goal is to see if this combination can slow or shrink the cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.